Welcome to our dedicated page for NATIONAL HEALTHCARE SEC filings (Ticker: NHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NATIONAL HEALTHCARE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NATIONAL HEALTHCARE's regulatory disclosures and financial reporting.
NATIONAL HEALTHCARE CORP director Sandra Y. Trail reported a compensation-related award of stock options. She received an option to purchase 7,500 shares of common stock at an exercise price of $171.42 per share, granted under the 2020 Omnibus Equity Incentive Plan on May 7, 2026.
The option becomes exercisable on May 7, 2027 and expires on May 6, 2031. Following this filing, Trail holds 7,500 shares of common stock directly and has several prior option grants outstanding with exercise prices of $94.66, $96.03, and $55.75 per share, each covering 7,500 underlying shares. The company notes the grant and its potential exercise are exempt from Section 16(b) under Rule 16b-3(d).
NATIONAL HEALTHCARE CORP director James Paul Abernathy reported an equity award and updated holdings. He received an option to purchase 7,500 shares of common stock at an exercise price of $171.42 per share, expiring on May 6, 2031. The options were granted under the 2020 Omnibus Equity Incentive Plan and are described as exempt from Section 16(b) under Rule 16b-3(d).
Following the reported entries, he directly holds 43,302 shares of common stock. He also holds previously granted options covering 7,500 shares at $94.66, 7,500 shares at $96.03, and 4,360 shares at $55.75, providing additional potential future share exposure if exercised.
National Healthcare Corp director William A. Adams received a grant of options on 7,500 shares of common stock. The options were granted on May 7, 2026 under the company’s 2020 Omnibus Equity Incentive Plan with a stated exercise price of $0.00 per share and expire on May 6, 2030. Following this award, Adams holds options covering 7,500 shares directly as reported in this filing. The grant and potential exercise are described as exempt from Section 16(b) under Rule 16b-3(d), indicating this is a routine equity-based compensation award for a board member.
National Healthcare Corp director David R. Gifford received a new stock option grant. He was granted options to purchase 7,500 shares of NHC common stock at an exercise price of $171.42 per share. The options were granted under the 2020 Omnibus Equity Incentive Plan and are scheduled to expire on May 6, 2030. The grant is reported as a compensation-related award and is exempt from Section 16(b) under Rule 16b-3(d).
National Healthcare Corp director Lisa Piercey received a grant of stock options as compensation. On May 7, 2026, she was awarded options to purchase 7,500 shares of common stock at an exercise price of $171.42 per share, expiring on May 6, 2030. The options were granted under the company’s 2020 Omnibus Equity Incentive Plan, with no cash paid at grant, and leave her holding 7,500 options following the transaction.
National Healthcare Corp director Robert G. Adams reported a new stock option grant. He received options covering 7,500 shares of common stock at an exercise price of $171.42 per share, expiring on May 6, 2031.
The options were granted on May 7, 2026 under the company’s 2020 Omnibus Equity Incentive Plan, with no cash paid for the grant. The filing also lists existing option awards from 2022–2025 and indirect holdings of common stock in a trust and a partnership, but no open‑market share purchases or sales.
NATIONAL HEALTHCARE CORP director Emil E. Hassan received a new stock option grant as part of equity compensation. On May 7, 2026, he was granted options to purchase 7,500 shares of common stock at an exercise price of $171.42, vesting beginning May 7, 2027 and expiring May 6, 2031, under the 2020 Omnibus Equity Incentive Plan. Following this grant, he directly holds 73,095 shares of common stock and several prior option awards, each covering 7,500 shares at exercise prices of $94.66, $96.03, $55.75, and $69.19 with expirations from 2027 through 2030.
National Healthcare Corp director Richard F. LaRoche Jr reported updated holdings and a new stock option grant. He now directly holds 213,260 shares of common stock in his or his wife's name. On May 7, 2026, he received an option to purchase 7,500 shares of common stock at an exercise price of $171.42 per share.
The new 2026 option grant, issued under the 2020 Omnibus Equity Incentive Plan, becomes exercisable on May 7, 2027 and expires on May 6, 2031. LaRoche also continues to hold prior option awards from 2022, 2023, 2024 and 2025, each covering 7,500 underlying shares at exercise prices ranging from $55.75 to $96.03 per share.
National HealthCare Corporation reported higher first-quarter 2026 results, with net operating revenues of $381.8M, up 2.2% from a year ago. Net income attributable to the company rose to $35.9M versus $32.2M, and diluted earnings per share increased to $2.27 from $2.07.
Excluding unrealized equity gains and share-based compensation, non-GAAP net income was $30.1M compared with $24.8M, a 21.1% increase, or $1.91 per diluted share. Skilled nursing occupancy averaged 90.0%, and companywide operating margins improved slightly as salaries, wages and benefits and other operating costs grew more slowly than revenues.
Operating cash flow strengthened to $62.5M, enabling the full repayment of $40.0M of credit facility debt and the repurchase of 97,720 shares for $16.3M. After quarter-end, NHC agreed to acquire the real estate of 32 skilled nursing and 3 independent living facilities from National Health Investors for $560M, expanding its owned real estate footprint in the southeastern U.S., subject to customary closing conditions.
National HealthCare Corporation declared a higher quarterly cash dividend, signaling a modest boost in shareholder returns. The company will pay a quarterly dividend of $0.67 per common share to shareholders of record on June 30, 2026, with payment on July 31, 2026. This dividend represents a 4.7% increase over the prior quarter’s regular common dividend, indicating steady, incremental growth in its cash distributions.
As of May 1, 2026, NHC affiliates operate 80 skilled nursing facilities with 10,323 beds, along with assisted and independent living communities, behavioral health hospitals, homecare and hospice agencies, and related services such as pharmacy and rehabilitation. The company also highlights typical healthcare industry risks and includes standard forward-looking statement cautions.